The POST-ACS Study

NCT05322200 on ClinicalTrials.gov · last registry update 2022-10-27

140 participants. Its estimated completion date, 28 April 2024, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Swansea Bay University Health Board
Sponsor type: Other
Enrollment: 140
Started: 2022-08-31
Primary completion: 2024-04-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated "Plaque Maps" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.

Conditions studied

Diabetes Mellitus · Acute Coronary Syndrome · Coronary Artery Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.